Status:
COMPLETED
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Centocor, Inc.
Conditions:
Arthritis, Psoriatic
Eligibility:
All Genders
Brief Summary
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
Detailed Description
This study population was chosen from a non-probability sample.
Eligibility Criteria
Inclusion
- Participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs.
Exclusion
- All according to contraindications in the label especially:
- Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
- Participants with moderate or severe heart failure (NYHA class III/IV).
- Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT00725296
Start Date
December 1 2004
End Date
July 1 2010
Last Update
November 5 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.